{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:43Z","timestamp":1793325763678,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U54DK126126"],"award-info":[{"award-number":["U54DK126126"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1053\/j.ajkd.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T13:50:17Z","timestamp":1729086617000},"page":"491-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Treatment of Autosomal-Dominant Polycystic Kidney Disease"],"prefix":"10.1053","volume":"85","author":[{"given":"Sara S.","family":"Jdiaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.ajkd.2024.08.008_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/ckj\/sfad087","article-title":"The ERA Registry Annual Report 2020: a summary","volume":"16","author":"Astley","year":"2023","journal-title":"Clin Kidney J"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2024.08.008_bib2","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.008_bib3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.34067\/KID.0004522021","article-title":"Autosomal dominant polycystic kidney disease prevalence among a Racially Diverse United States population, 2002 through 2018","volume":"2","author":"Aung","year":"2021","journal-title":"Kidney360"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.008_bib4","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1001\/jama.2022.22847","article-title":"Exome sequencing of a clinical population for autosomal dominant polycystic kidney disease","volume":"328","author":"Chang","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2215\/CJN.05900519","article-title":"Epidemiology of autosomal dominant polycystic kidney disease in Olmsted County","volume":"15","author":"Suwabe","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.008_bib6","first-page":"1356","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.008_bib9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1159\/000518255","article-title":"predicting future renal function decline in patients with autosomal dominant polycystic kidney disease using Mayo Clinic classification","volume":"52","author":"Borrego Utiel","year":"2021","journal-title":"Am J Nephrol"},{"issue":"20","key":"10.1053\/j.ajkd.2024.08.008_bib10","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ekir.2023.02.1073","article-title":"OVERTURE: a worldwide, prospective, observational study of disease characteristics in patients with ADPKD","volume":"8","author":"Perrone","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","article-title":"Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD Trials","volume":"71","author":"Brosnahan","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.008_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A\u00a0comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2215\/CJN.14931121","article-title":"Total kidney volume measurements in ADPKD by 3D and ellipsoid ultrasound in comparison with magnetic resonance imaging","volume":"17","author":"Akbari","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib18","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9147","key":"10.1053\/j.ajkd.2024.08.008_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2024.08.008_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"15","key":"10.1053\/j.ajkd.2024.08.008_bib22","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1073\/pnas.86.15.6007","article-title":"Renal epithelial cyst formation and enlargement in\u00a0vitro: dependence on cAMP","volume":"86","author":"Mangoo-Karim","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.1053\/j.ajkd.2024.08.008_bib23","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2024.08.008_bib24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.008_bib25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.008_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.008_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100639","article-title":"Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies","volume":"5","author":"Chebib","year":"2023","journal-title":"Kidney Med"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.008_bib31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","article-title":"Evaluating the impact of a risk evaluation and mitigation strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Estilo","year":"2022","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib32","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 Trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97113-w","article-title":"The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial","volume":"11","author":"Uchiyama","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.008_bib35","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ndt\/gfaa150","article-title":"Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study","volume":"36","author":"Kramers","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.008_bib36","first-page":"1276","article-title":"Review of tolvaptan\u2019s pharmacokinetic and pharmacodynamic properties and drug interactions","volume":"3","author":"Bhatt","year":"2014","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.008_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00228-011-1106-4","article-title":"Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects","volume":"68","author":"Shoaf","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"10.1053\/j.ajkd.2024.08.008_bib39","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.008_bib40","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2024.08.008_bib41","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.ki.5002629","article-title":"Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy\/+ rat","volume":"73","author":"Nagao","year":"2008","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","article-title":"Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage According to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis","volume":"76","author":"Etminan","year":"2019","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.08.008_bib44","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/ndt\/gfac027","article-title":"Diagnosis and risk factors for intracranial aneurysms in autosomal polycystic kidney disease: a cross-sectional study from the Genkyst cohort","volume":"37","author":"Lef\u00e8vre","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1681\/ASN.V121194","article-title":"Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects","volume":"12","author":"Ecder","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"22","key":"10.1053\/j.ajkd.2024.08.008_bib46","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib47","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A\u00a0case for water in the treatment of polycystic kidney disease","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100021","article-title":"Prescribed water intake in autosomal dominant polycystic kidney disease","volume":"1","author":"Rangan","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.008_bib49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.008_bib50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib51","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.008_bib53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.008_bib54","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.xkme.2021.03.004","article-title":"Pain and obesity in autosomal dominant polycystic kidney disease: a post hoc analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) studies","volume":"3","author":"Nowak","year":"2021","journal-title":"Kidney Med"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.008_bib55","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A\u00a0mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.008_bib56","first-page":"175","article-title":"Effects of smoking on ADPKD: frequency of vascular events and concentrations of soluble CD40 ligand","volume":"3","author":"Brody","year":"2015","journal-title":"General Med"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93633-7","article-title":"Smoking accelerates renal cystic disease and worsens cardiac phenotype in Pkd1-deficient mice","volume":"11","author":"Sousa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.ajkd.2024.08.008_bib58","article-title":"Large retroperitoneal haemorrhage following cyst rupture in a patient with autosomal dominant polycystic kidney disease","volume":"2017","author":"Mabillard","year":"2017","journal-title":"Case Rep Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib59","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.33594\/000000072","article-title":"Caffeine accelerates cystic kidney disease in a Pkd1-deficient mouse model","volume":"52","author":"Meca","year":"2019","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib60","first-page":"87","article-title":"Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a prospective longitudinal cohort study","volume":"31","author":"Girardat-Rotar","year":"2018","journal-title":"J\u00a0Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12882-018-1182-0","article-title":"Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort","volume":"19","author":"McKenzie","year":"2018","journal-title":"BMC Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.008_bib62","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1590\/S0100-879X2012007500120","article-title":"Caffeine intake by patients with autosomal dominant polycystic kidney disease","volume":"45","author":"Vendramini","year":"2012","journal-title":"Braz J Med Biol Res"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.008_bib63","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib64","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2024.08.008_bib65","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib66","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0272-6386(03)00368-8","article-title":"Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease","volume":"41","author":"Bleeker-Rovers","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib67","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0272-6386(85)80102-5","article-title":"Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease","volume":"6","author":"Bennett","year":"1985","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib68","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1053\/j.ajkd.2005.09.021","article-title":"Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease","volume":"47","author":"Hiyama","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib69","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1089\/end.2012.0529","article-title":"Surgical cyst decortication in autosomal dominant polycystic kidney disease","volume":"27","author":"Millar","year":"2013","journal-title":"J\u00a0Endourol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.008_bib70","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"issue":"11","key":"10.1053\/j.ajkd.2024.08.008_bib71","article-title":"Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial","volume":"4","author":"Cukoski","year":"2023","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.008_bib72","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.008_bib73","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2215\/CJN.11260821","article-title":"Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: a randomized crossover trial","volume":"17","author":"Kramers","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.008_bib74","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","article-title":"Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?","volume":"19","author":"Pisani","year":"2018","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.008_bib76","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2024.08.008_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107423","article-title":"Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: design and baseline characteristics","volume":"137","author":"Gitomer","year":"2024","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib78","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.008_bib79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","article-title":"Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial","volume":"18","author":"Mekahli","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.008_bib80","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfx188","article-title":"Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial","volume":"33","author":"Cornec-Le Gall","year":"2018","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624010321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624010321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T18:28:10Z","timestamp":1742668090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624010321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0272638624010321"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.08.008","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Autosomal-Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}